Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 9:56 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 1,280 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Infection Prophylaxis Clear all

Conditions: HIV Counseling and Testing, HIV Infections
Interventions: Educational video; Procedure
Lead sponsor: North Bronx Healthcare Network; Other
Eligibility: 18 Years and older
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: HIV Infections
Interventions: POC NAT & Adherence Intervention; Diagnostic Test
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 194 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Sars-CoV-2 Infection
Interventions: Peginterferon lambda alfa-1a subcutaneous injection, Saline; Drug · Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Herpes Simplex
Interventions: acyclovir sodium; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 120 Years
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: HIV
Interventions: Dolutegravir 0.5 mg/kg liquid suspension (starts at 0-5 days of life), Dolutegravir 5 mg Dispersible Tablets (single doses), Dolutegravir 5 mg Dispersible Tablets (chronic dose), Dolutegravir 0.5 mg/kg liquid suspension (starts at 2-5 days of life); Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Not listed
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 8
States / cities: Los Angeles, California • Aurora, Colorado • Atlanta, Georgia + 4 more

Conditions: Haemophilus Influenzae Type b, Neisseria Meningitidis
Interventions: GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine combined (792014), PedvaxHIB, Prevnar, M-M-R II, Varivax; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Months to 15 Months
Enrollment: 4,021 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 55
States / cities: Birmingham, Alabama • Benton, Arkansas • Jonesboro, Arkansas + 45 more

Conditions: Surgical Site Infection, Vaginal Cuff Cellulitis, Bacterial Vaginosis
Interventions: Clindamycin Vaginal Gel; Drug
Lead sponsor: Baylor Research Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 900 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Temple, Texas

Conditions: Heart Transplant Infection Prevention
Interventions: PCV15; Biological
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Marburg Hemorrhagic Fever
Interventions: AVI-7288, Placebo; Drug · Other
Lead sponsor: Sarepta Therapeutics, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: HIV, HIV Pre-exposure Prophylaxis
Interventions: MK-8527, Placebo to MK-8527; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 352 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 10
States / cities: North Hollywood, California • San Francisco, California • Hallandale, Florida + 7 more

Conditions: Cystitis, Urinary Tract Infections
Interventions: Frio Mouth Rinse; Drug
Lead sponsor: Biomedical Development Corporation; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Houston, Texas

Conditions: HIV/AIDS
Interventions: JIC; Behavioral
Lead sponsor: Columbia University; Other
Eligibility: 14 Years to 22 Years
Enrollment: 8,270 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: COVID-19
Interventions: Education, Motivational; Other
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 778 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: COVID-19, Coronavirus Infection, Sars-CoV2, Corona Virus Infection, COVID, Coronavirus, Coronavirus-19, Coronavirus 19
Interventions: Hydroxychloroquine, Vitamin C, Vitamin D, Zinc; Drug · Dietary Supplement
Lead sponsor: ProgenaBiome; Other
Eligibility: 18 Years and older
Enrollment: 254 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Ventura, California

Conditions: Human Immunodeficiency Virus
Interventions: Pharmacy Delivered PrEP Intervention; Behavioral
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Clostridioides Difficile, Vancomycin Resistance Enterococcus Faecium
Interventions: Vancomycin (POC); Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 65 Years to 100 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2027
U.S. locations: 1
States / cities: Glen Burnie, Maryland

Conditions: Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions: Pentamidine isethionate; Drug
Lead sponsor: Fisons; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Esophagitis, Pneumonitis, Non-Small Cell Lung Carcinoma
Interventions: Amifostine; Drug
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years and older
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 24
States / cities: Los Angeles, California • Sacramento, California • Torrington, Connecticut + 21 more

Conditions: Pre-Exposure Prophylaxis of HIV Infection
Interventions: Oral Lenacapavir (LEN), F/TDF, Sub-cutaneous (SC) Lenacapavir (LEN), Placebo SC LEN, PTM F/TDF, PTM Oral LEN, F/TAF (for US participants only); Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 16 Years and older
Enrollment: 3,292 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2028
U.S. locations: 60
States / cities: Birmingham, Alabama • Loma Linda, California • Los Angeles, California + 43 more

Conditions: Aspergillosis, Candidiasis, Fungal Diseases, Mycoses
Interventions: Voriconazole; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2001
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: CIN 2/3, HPV Infection, Pre-Cancerous Dysplasia, Cervical Dysplasia, HPV Related Disease
Interventions: Artesunate vaginal insert, Placebo vaginal insert; Drug
Lead sponsor: Frantz Viral Therapeutics, LLC; Industry
Eligibility: 25 Years to 100 Years · Female only
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 7
States / cities: Fort Myers, Florida • Ann Arbor, Michigan • Cleveland, Ohio + 2 more

Conditions: Hepatitis B
Interventions: 1018 ISS immunostimulatory oligonucleotide with HBV surface antigen, Hepatitis B Vaccine (Recombinant); Biological
Lead sponsor: Dynavax Technologies Corporation; Industry
Eligibility: 40 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 4
States / cities: Costa Mesa, California • Brooklyn Center, Minnesota • Austin, Texas + 1 more

Conditions: Cytomegalovirus Disease, Kidney Transplant Infection
Interventions: Brincidofovir, Valganciclovir; Drug
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 3
States / cities: Los Angeles, California • Aurora, Colorado • New Haven, Connecticut

Conditions: HPV Vaccination, Uptake Vaccination, Series Completion
Interventions: PREVENT; Behavioral
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 335 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Seattle, Washington

Search by objective public record fields.

An Educational HIV Pre-Test Counseling Video Program for Off Hours Testing in the ED: A Randomized Control Trial

Improving HIV Diagnosis, Linkage to Care, and Prevention Services With HIV Point-of-Care Nucleic Acid Tests

Peginterferon Lambda-1a for the Prevention and Treatment of SARS-CoV-2 (COVID-19) Infection

Acyclovir in Preventing Herpes Simplex Virus Infection in Patients With Neutropenia

A Study of the Safety, Tolerability, and Pharmacokinetics of Dolutegravir in Neonates Exposed to HIV-1

Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 12 to 15 Months of Age.

Prevention of Vaginal Cuff Infection After Hysterectomy by Addition of Vaginal Clindamycin

MISP 60528 Pneumococcal Vaccination

A Study to Assess the Safety, Tolerability and Pharmacokinetics of AVI-7288 in Healthy Adult Volunteers

Safety and Pharmacokinetic Study of Oral MK-8527 QM in Participants at Low-Risk for HIV-1 Infection (MK-8527-007)

Treatment and/or Prevention of Urinary Tract Infections

Assessing the Impact of an Educational HIV Prevention Intervention in Zambia

Social Network Diffusion of COVID-19 Prevention for Diverse Criminal Legal Involved Communities

A Study of Hydroxychloroquine, Vitamin C, Vitamin D, and Zinc for the Prevention of COVID-19 Infection

Pharmacy-based Pre-exposure Prophylaxis

Primary Prophylaxis of Clostridioides Difficile Infection With Oral Vancomycin

The Safety and Effectiveness of Pentamidine in the Prevention of Pneumocystis Carinii Pneumonia (PCP) in Patients With AIDS Who Have Had PCP Before

Subcutaneous Amifostine (Ethyol®) in the Prevention of Radiochemotherapy-Induced Esophagitis and Pneumonitis in Patients With Unresectable Non-Small Cell Lung Cancer

Pre-Exposure Prophylaxis Study of Lenacapavir in Cisgender Men, Transgender Women, Transgender Men, and Gender Nonbinary People at Risk for HIV Infection

Voriconazole to Prevent Systemic Fungal Infections in Children

Artesunate Vaginal Inserts for the Treatment of Cervical Intraepithelial Neoplasia (CIN2/3)

Safety of HEPLISAV™ Hepatitis B Virus Vaccine in End-stage Kidney Failure Patients

A Phase 3 Study of Brincidofovir Versus Valganciclovir for the Prevention of Cytomegalovirus

PREVENT Pilot HPV - Related Cancers Trial